Insight

Dec 12, 2023, 17:44

Piotr Wysocki: SABCS2023 – Adjuvant chemoimmunotherapy does not benefit TNBC patients

Piotr Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn:

“SABCS2023 – Adjuvant chemoimmunotherapy does not benefit TNBC patients

A large phase 3 ALEXANDRA/IMpassion030 study evaluated the addition of atezolizumab to standard adjuvant chemotherapy 12xPaclitaxel –> 4x ddAC/EC in a population of stage II-III TNBC patients (N=2300). After a median follow-up of approx. 25 months the study failed to demonstrate the benefit of adding atezolizumab to chemotherapy with HR for iDFS (primary endpoint) – 1.12 (95% CI 0.87–1.45) p=0.37.

This study clearly supports the current standard of using chemoimmunotherapy in neoadjuvant settings in TNBC patients. However, the question if adjuvant immunotherapy is needed in patients treated with neoadjuvant chemoimmunotherapy still remains unanswered.”

Source: Piotr Wysocki/LinkedIn

Adjuvant Therapy atezolizumab Breast Cancer cancer chemoimmunotherapy chemotherapy ddAC/EC immunotherapy OncoDaily Oncology Paclitaxel Piotr Wysocki TNBC

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more